Market Cap (In USD)
2.62 Million
Revenue (In USD)
-
Net Income (In USD)
-789.34 Thousand
Avg. Volume
-
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.1557-0.24
- PE
- -
- EPS
- -
- Beta Value
- 0.791
- ISIN
- US74737F1012
- CUSIP
- 74737F101
- CIK
- 1689084
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Jonah Martin Meer
- Employee Count
- -
- Website
- https://qrons.com
- Ipo Date
- 2017-09-12
- Details
- Qrons Inc., a biotechnology company, engages in development of biotech products, treatments, and technologies to combat neuronal diseases. Its product candidates include QS100, an injury specific, 3D printable, implantable mesenchymal stem cells (MSCs)-synthetic hydrogel to treat penetrating brain injuries; and QS200, an injectable MSCs-synthetic hydrogel for the treatment of concussions and other diffused axonal injuries. The company was formerly known as BioLabMart Inc. and changed its name to Qrons Inc. in August 2017. Qrons Inc. was incorporated in 2016 and is based in Long Island City, New York.
More Stocks
-
601008
-
8273Izumi Co., Ltd.
8273
-
PALIPalisade Bio, Inc.
PALI
-
CACO
-
HSCHFH-Source Holdings Ltd.
HSCHF
-
CNSL
-
BLONFCO2 Gro Inc.
BLONF
-
CTRMCastor Maritime Inc.
CTRM